Acute Respiratory Distress Syndrome after Topotecan Therapy in a Patient with Small Cell Lung Cancer
![]() ![]() |
Tae, Jung Hyun
(Department of Internal Medicine, Ewha Womans University School of Medicine)
Lee, Jin Hwa (Department of Internal Medicine, Ewha Womans University School of Medicine) Kim, Yoon Kyung (Department of Radiology, Ewha Womans University School of Medicine) Sim, Yun Su (Department of Internal Medicine, Ewha Womans University School of Medicine) Lee, Kyung Jong (Department of Internal Medicine, Ewha Womans University School of Medicine) Noh, Young Wook (Department of Internal Medicine, Ewha Womans University School of Medicine) Park, Jae Jung (Department of Internal Medicine, Ewha Womans University School of Medicine) Ryu, Yon Ju (Department of Internal Medicine, Ewha Womans University School of Medicine) Chun, Eun Mi (Department of Internal Medicine, Ewha Womans University School of Medicine) Chang, Jung Hyun (Department of Internal Medicine, Ewha Womans University School of Medicine) |
1 | Cooper S, Spiro SG. Small cell lung cancer: treatment review. Respirology 2006;11:241-8. DOI ScienceOn |
2 | Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-59. DOI |
3 | Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004;25:53-64. DOI ScienceOn |
4 | Maitland ML, Wilcox R, Hogarth DK, Desai AA, Caligiuri P, Abrahams C, et al. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer 2006;54:243-5. DOI ScienceOn |
5 | Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20. DOI |
6 | Limper AH. Drug-induced pulmonary disease. In: Mason RJ, Broaddus VC, Murray JF, Nadel JA, editors. Murray and Nadel's textbook of respiratory medicine. 4th ed. Philadelphia: Elsevier Saunders; 2005. p. 1888-912. |
7 | Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed smallcell lung cancer. J Clin Oncol 1992;10:1225-9. DOI |
8 | Edgerton CC, Gilman M, Roth BJ. Topotecan-induced bronchiolitis. South Med J 2004;97:699-701. DOI ScienceOn |
9 | Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-92. DOI ScienceOn |
10 | Madarnas Y, Webster P, Shorter AM, Bjarnason GA. Irinotecan-associated pulmonary toxicity. Anticancer Drugs 2000;11:709-13. DOI |
11 | Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090-6. DOI |
12 | Maksymiuk AW, Marschke RF Jr, Tazelaar HD, Grill J, Nair S, Marks RS, et al. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 1998; 21:610-3. DOI ScienceOn |
13 | Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use: two distinct patterns. Am J Respir Crit Care Med 1996;154:1851-6. DOI ScienceOn |
14 | MacCallum C, Gillenwater HH. Second-line treatment of small-cell lung cancer. Curr Oncol Rep 2006;8:258-64. DOI ScienceOn |
![]() |